Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
US8614183B2 · kind B2 · utility
6Cited by
25References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 2010 |
| Grant date | Dec 24, 2013 |
| Priority date | — |
| Expiry date | Nov 12, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.